Abstract
Regulatory agencies have a key role in facilitating the development of new drugs for Alzheimer disease, particularly given the challenges associated with early intervention. Here, we highlight the strategies of the European Medicines Agency to help address such challenges.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Higher FT4 or TSH below the normal range are associated with increased risk of dementia: a meta-analysis of 11 studies
Scientific Reports Open Access 25 August 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
FURTHER INFORMATION
Qualification opinion of Alzheimer's disease novel methodologies/biomarkers
Rights and permissions
About this article
Cite this article
Haas, M., Mantua, V., Haberkamp, M. et al. The European Medicines Agency's strategies to meet the challenges of Alzheimer disease. Nat Rev Drug Discov 14, 221–222 (2015). https://doi.org/10.1038/nrd4585
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4585